2014•Therapeutic Drug MonitoringRequires access

Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?

Étienne Brochot, Sandra Bodeau, Gilles Duverlie

Open publisher page 4 citations

Abstract

Brochot, Etienne PharmD, PhD; Bodeau, Sandra PharmD, PhD; Duverlie, Gilles PharmD, PhD Author Information

About this research paper

What this paper is about

Brochot, Etienne PharmD, PhD; Bodeau, Sandra PharmD, PhD; Duverlie, Gilles PharmD, PhD Author Information

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Brochot, Etienne PharmD, PhD; Bodeau, Sandra PharmD, PhD; Duverlie, Gilles PharmD, PhD Author Information

Key concepts: Ribavirin, Sofosbuvir, Medicine, Genotype, Drug, Therapeutic drug monitoring, Virology, Pharmacology

Back to paper search Browse research topics Original source

Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role? — Research Paper | ScholarLens

Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?

About this research paper

What this paper is about

Why it matters

Key contribution

Method / approach

Main findings

Limitations

Applications

Available abstract

Related papers